MaaT Pharma Reports Cash and Revenues for Second Quarter 2022

MaaT Pharma (EURONEXT: MAAT the Company), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of June 30, 2022, and its revenues for the second quarter of 2022.